The purpose of this study was to investigate the effect of pitavastatin or pitavastatin and ezetimibe combination therapy on glucose metabolism compared to atorvastatin in patients with atherosclerotic cardiovascular disease with metabolic syndrome.
Patients with dyslipidemia
Patient with diagnosis of clinical atherosclerotic cardiovascular disease (acute coronary syndrome, history of myocardial infarction, stable or unstable angina, history of coronary artery reperfusion, stroke or transient stroke, history of peripheral arterial disease or peripheral arterial reperfusion)
Patients with metabolic syndrome but without diabetes
Diagnosis of clinical atherosclerotic cardiovascular disease within 1 year
Acute liver disease or persistent unexplained serum AST or ALT three times the upper limit of normal
Allergy or hypersensitivity to statins or ezetimibe
Solid organ transplant recipients